Rare, Protein-truncating Variants in , and , but Not , Are Associated with Increased Breast Cancer Risks

Overview

Journal J Med Genet

Specialty Genetics

Date 2017 Aug 6

PMID 28779002

Citations 43

Authors

Brennan Decker

Jamie Allen

Craig Luccarini

Karen A Pooley

Mitul Shah

Manjeet K Bolla

Qin Wang

Shahana Ahmed

Caroline Baynes

Don M Conroy

Judith Brown

Robert Luben

Elaine A Ostrander

Paul Dp Pharoah

Alison M Dunning

Douglas F Easton

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) is the most common malignancy in women and has a major heritable component. The risks associated with most rare susceptibility variants are not well estimated. To better characterise the contribution of variants in , , and , we sequenced their coding regions in 13 087 BC cases and 5488 controls from East Anglia, UK.

Methods: Gene coding regions were enriched via PCR, sequenced, variant called and filtered for quality. ORs for BC risk were estimated separately for carriers of truncating variants and of rare missense variants, which were further subdivided by functional domain and pathogenicity as predicted by four algorithms.

Results: Truncating variants in (OR=4.69, 95% CI 2.27 to 9.68), (OR=3.26; 95% CI 1.82 to 6.46) and (OR=3.11; 95% CI 2.15 to 4.69), but not (OR=0.94; 95% CI 0.26 to 4.19) were associated with increased BC risk. Truncating variants in and were more strongly associated with risk of oestrogen receptor (ER)-positive than ER-negative disease, while those in were associated with similar risks for both subtypes. There was also some evidence that missense variants in , and may contribute to BC risk, but larger studies are necessary to quantify the magnitude of this effect.

Conclusions: Truncating variants in are associated with a higher risk of BC than those in or . A substantial risk of BC due to truncating variants can be excluded.

Citing Articles

Clinicopathological Features and Oncological Outcomes of Germline Partner and Localizer of Breast Cancer 2-Mutated Breast Cancer in Korea.

Sae-Lim C, Jo S, Park S, Kweon T, Lee J, Lee Y J Breast Cancer. 2025; 27(6):372-382.

PMID: 39761944 PMC: 11710906. DOI: 10.4048/jbc.2024.0146.

High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia.

Shumilova S, Danishevich A, Nikolaev S, Krasnov G, Ikonnikova A, Isaeva D Int J Mol Sci. 2024; 25(23).

PMID: 39684352 PMC: 11641773. DOI: 10.3390/ijms252312640.

Genetic landscape of Romanian PPGLs.

Lider-Burciulescu S, Gheorghiu M, Braha E, Stanescu L, Patocs A, Badiu C J Cell Mol Med. 2024; 28(23):e70204.

PMID: 39673085 PMC: 11645294. DOI: 10.1111/jcmm.70204.

Germline Variant Spectrum in Southern Italian High-Risk Hereditary Breast Cancer Patients: Insights from Multi-Gene Panel Testing.

Rocca V, Lo Feudo E, Dinatolo F, Lavano S, Bilotta A, Amato R Curr Issues Mol Biol. 2024; 46(11):13003-13020.

PMID: 39590369 PMC: 11592649. DOI: 10.3390/cimb46110775.

Strong association of single nucleotide polymorphisms in BRCA1, ATM, and CHEK2 with breast cancer susceptibility in a sub-population of Iranian women.

Jahangiri S, Abdan Z, Soroush A, Houshmand M, Aznab M Breast Cancer Res Treat. 2024; 209(2):397-404.

PMID: 39436532 DOI: 10.1007/s10549-024-07503-7.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A . A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007; 446(7133):316-9. DOI: 10.1038/nature05609. View

Park D, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F . Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet. 2012; 90(4):734-9. PMC: 3322233. DOI: 10.1016/j.ajhg.2012.02.027. View

Tavtigian S, Oefner P, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F . Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009; 85(4):427-46. PMC: 2756555. DOI: 10.1016/j.ajhg.2009.08.018. View

Schmidt M, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank M . Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol. 2016; 34(23):2750-60. PMC: 5019754. DOI: 10.1200/JCO.2016.66.5844. View

Yeo G, Burge C . Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004; 11(2-3):377-94. DOI: 10.1089/1066527041410418. View

Tavtigian S, Deffenbaugh A, Yin L, Judkins T, Scholl T, Samollow P . Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2005; 43(4):295-305. PMC: 2563222. DOI: 10.1136/jmg.2005.033878. View

Easton D, Pharoah P, Antoniou A, Tischkowitz M, Tavtigian S, Nathanson K . Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015; 372(23):2243-57. PMC: 4610139. DOI: 10.1056/NEJMsr1501341. View

Lee A, Cunningham A, Kuchenbaecker K, Mavaddat N, Easton D, Antoniou A . BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2013; 110(2):535-45. PMC: 3899766. DOI: 10.1038/bjc.2013.730. View

10.

Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M . Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2):78-85. DOI: 10.1056/NEJM200007133430201. View

11.

Naslund-Koch C, Nordestgaard B, Bojesen S . Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. J Clin Oncol. 2016; 34(11):1208-16. DOI: 10.1200/JCO.2015.63.3594. View

12.

Antoniou A, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J . Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014; 371(6):497-506. PMC: 4157599. DOI: 10.1056/NEJMoa1400382. View

13.

Day N, Oakes S, Luben R, Khaw K, Bingham S, Welch A . EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999; 80 Suppl 1:95-103. View

14.

Van der Auwera G, Carneiro M, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A . From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2014; 43:11.10.1-11.10.33. PMC: 4243306. DOI: 10.1002/0471250953.bi1110s43. View

15.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

16.

Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D . CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer. 2004; 111(4):543-7. DOI: 10.1002/ijc.20299. View

17.

Reese M, Eeckman F, Kulp D, Haussler D . Improved splice site detection in Genie. J Comput Biol. 1997; 4(3):311-23. DOI: 10.1089/cmb.1997.4.311. View

18.

Young E, Feng B, Stark A, Damiola F, Durand G, Forey N . Multigene testing of moderate-risk genes: be mindful of the missense. J Med Genet. 2016; 53(6):366-76. PMC: 4893078. DOI: 10.1136/jmedgenet-2015-103398. View

19.

Li H . Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics. 2012; 28(14):1838-44. PMC: 3389770. DOI: 10.1093/bioinformatics/bts280. View

20.

Stankovic T, Kidd A, Sutcliffe A, McGuire G, Robinson P, Weber P . ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998; 62(2):334-45. PMC: 1376883. DOI: 10.1086/301706. View